Exelixis Inc (NQ: EXEL )

21.82 USD -0.02 (-0.09%)

Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2021 Add to My Watchlist

Price and Volume

Volume	3,196,876
Open	22.00
Bid (Size)	21.45 (2)
Ask (Size)	22.00 (5)
Prev. Close	21.84
Today's Range	21.67 - 22.08
52wk Range	16.19 - 25.77
Shares Outstanding	315,048,788
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

October 14, 2021

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and...

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

October 14, 2021

Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today announced that Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to...

Performance

YTD	+6.28%	+6.28%
1 Month	+6.23%	+6.23%
3 Month	+33.87%	+33.87%
6 Month	-8.09%	-8.09%
1 Year	-6.07%	-6.07%

More News

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2

September 20, 2021

Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021

September 18, 2021

First Week of EXEL December 17th Options Trading

October 15, 2021

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

September 17, 2021

Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckM

September 16, 2021

Exelixis Statement on the Passing of Two Senior Executives

September 06, 2021

Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation

September 20, 2021

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

September 01, 2021

A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2%

September 20, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.